ClinicalTrials.gg
Drug

Inclisiran clinical trials

Also written KJX839, ALN-PCSSC and Leqvio.

studies test it
51
open now
18
in phase 3
23
first study started
2014

How each study uses inclisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the inclisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Dec 2021 · LEQVIO · NDA 214012 (FDA, Drugs@FDA)
European Union
9 Dec 2020 · Leqvio · EMEA/H/C/005333 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Inclisiran
31
Inclisiran Sodium
8
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
3
Inclisiran sodium 300 mg
2
PCSK9 synthesis inhibitor
2

Brand

Leqvio
4

Development codes

KJX839
18
ALN-PCSSC
6

Studies by the year they started

51 studies that test it; most in 2024 (11)

Studies that test inclisiran, by start year
YearStudies
20141
20162
20175
20181
20192
20219
20222
20235
202411
20257
20266

Who runs them

Industry 37 · Other 14

Novartis Pharmaceuticals (30) · The Medicines Company (6) · Duke University (2) · University of Oxford (1) · University of Cambridge (1) · Alnylam Pharmaceuticals (1) · Seoul National University Bundang Hospital (1) · First Affiliated Hospital of Xinjiang Medical University (1)

Often tested with

Tested in the same studies.

Alirocumab (2) · Pelacarsen (1) · Statins (1) · Ezetimibe (1) · Bempedoic acid (1) · Evolocumab (1) · QCZ484 (1) · Bempedoic Acid/Ezetimibe (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 10, 2 in phase 3

Studies that test inclisiran, phase 3 first.

Studies

Open first, then newest update. How each study uses inclisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 51

See all 51 studies that test inclisiran →

Given beside what is tested · 1 — inclisiran is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with inclisiran

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered1

Codes

What other systems call inclisiran · ClinicalTrials.gg INT006414

  • MeSH (NLM) C585830ALN-PCSConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) UOW2C71PG5INCLISIRANConfirmed FDA, NLM, Wikidata
  • RxNorm 2588243One source FDA
  • Wikidata Q48969359inclisiranConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C170062InclisiranOne source FDA
  • DrugBank DB14901One source Wikidata

Also registered as inclisiran sodium (UNII UPC6BTX7PY · RxNorm 2588259).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.